Barclays PLC Cerevel Therapeutics Holdings, Inc. Transaction History

Barclays PLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$38.96 - $42.75 $1.68 Million - $1.84 Million	-43,083 Reduced 45.86%	50,865 $2.08 Million
Q1 2024 May 15, 2024	SELL	$40.88 - $43.27 $10.6 Million - $11.2 Million	-258,414 Reduced 73.34%	93,948 $3.97 Million
Q4 2023 Feb 15, 2024	BUY	$20.27 - $42.44 $4.18 Million - $8.76 Million	206,452 Added 141.49%	352,362 $14.9 Million
Q3 2023 Nov 07, 2023	BUY	$20.26 - $31.91 $295,147 - $464,864	14,568 Added 11.09%	145,910 $3.19 Million
Q2 2023 Aug 03, 2023	SELL	$23.9 - $35.38 $11.2 Million - $16.6 Million	-469,712 Reduced 78.15%	131,342 $4.18 Million
Q1 2023 May 04, 2023	BUY	$22.82 - $35.32 $3.3 Million - $5.1 Million	144,439 Added 31.63%	601,054 $14.7 Million
Q4 2022 Feb 13, 2023	BUY	$25.35 - $31.96 $9.1 Million - $11.5 Million	358,880 Added 367.2%	456,615 $14.4 Million
Q3 2022 Nov 03, 2022	BUY	$25.5 - $41.42 $2.42 Million - $3.93 Million	94,920 Added 3371.94%	97,735 $2.76 Million
Q2 2022 Aug 12, 2022	SELL	$20.62 - $37.15 $82,521 - $148,674	-4,002 Reduced 58.71%	2,815 $74,000
Q1 2022 May 16, 2022	BUY	$23.5 - $35.38 $160,199 - $241,185	6,817 New	6,817 $239,000

5.01M

3.3K

Ticker CERE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 155,752,000
Description
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

Stay updated on Barclays PLC with notifications on news.